Joan Ohayon Selected Research

Daclizumab (Zenapax)

3/2016	Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
3/2014	Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
4/2013	The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.
1/2013	CNS vasculitis in a patient with MS on daclizumab monotherapy.
4/2009	Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
6/2004	Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joan Ohayon Research Topics

Disease

16	Multiple Sclerosis 01/2022 - 06/2004
5	Inflammation (Inflammations) 01/2016 - 04/2009
3	Atrophy 01/2020 - 04/2013
2	Neuroinflammatory Diseases 11/2021 - 04/2017
2	Progressive Multifocal Leukoencephalopathy 01/2021 - 01/2019
2	Nervous System Diseases (Neurological Disorders) 01/2021 - 01/2014
2	Relapsing-Remitting Multiple Sclerosis 04/2013 - 01/2009
2	Disease Progression 04/2009 - 04/2005
1	Infections 01/2021
1	Spinal Cord Diseases 01/2021
1	Tropical Spastic Paraparesis (Tropical Spastic Paraplegia) 01/2021
1	Body Weight (Weight, Body) 01/2019
1	Virus Diseases (Viral Diseases) 04/2017
1	Exanthema (Rash) 03/2014
1	Alopecia (Baldness) 03/2014
1	Lymphadenopathy 03/2014
1	Central Nervous System Vasculitis 01/2013
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 10/2009

Drug/Important Bio-Agent (IBA)

6	Daclizumab (Zenapax)FDA Link 03/2016 - 06/2004
4	GadoliniumIBA 12/2019 - 09/2011
3	Monoclonal AntibodiesIBA 01/2016 - 06/2004
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2017
2	Interferon-betaIBA 01/2009 - 06/2004
1	Complement C3 (C3 Complement)IBA 11/2021
1	teriflunomideIBA 01/2021
1	AntigensIBA 01/2021
1	pembrolizumabIBA 01/2019
1	daclizumab HYPIBA 03/2016
1	Pharmaceutical PreparationsIBA 01/2016
1	Rituximab (Mabthera)FDA Link 01/2016
1	AS 8IBA 01/2016
1	Viral DNAIBA 01/2014
1	InterferonsIBA 04/2013
1	Proteins (Proteins, Gene)FDA Link 09/2011
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 10/2009
1	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 10/2009
1	RolipramIBA 10/2009
1	Neutralizing AntibodiesIBA 01/2009
1	Interferon beta-1b (Betaseron)FDA Link 12/2008

Therapy/Procedure

5	Therapeutics 01/2020 - 06/2004
1	Immunotherapy 01/2021
1	Duration of Therapy 03/2014